Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Single-molecule profiling of full-length Tau isoforms and phosphorylated proteoforms

Project description

Advanced Alzheimer’s disease diagnostic tool

One of the central features of Alzheimer's disease (AD) is the abnormal modification and aggregation of Tau proteins, which disrupt brain function. Detecting these changes early is vital for AD diagnosis and treatment monitoring. Existing tools consist of immunoassays and mass spectrometry but face limitations in sensitivity and practicality for clinical use. With the support of the Marie Skłodowska-Curie Action programme, the SPoTIP project will develop a novel diagnostic tool for detecting single Tau molecules in real time and with great sensitivity. This tool is based on nanopore technology and will be able to detect all Tau modifications including disease-relevant phosphorylations and truncations. Using this tool in the clinic will lead to early detection of AD and tauopathies.

Objective

Abnormal post-translational modifications (PTMs) can lead to the aggregation of Tau proteins, which characterize a wide range of neurodegenerative diseases known as tauopathies. Some abnormal Tau proteins will be released into biological fluids, providing a chance for minimally- or non-invasive diagnosis. For Alzheimer's Disease (AD), site-specific phosphorylations and truncations are representative PTMs that have been proved as biomarkers for its early diagnosis and progression monitoring. To detect and quantify these abnormal Tau proteoforms, two methodologies—immunoassays and mass spectrometry (MS)—are frequently employed. However, both of them encounter significant challenges in clinical trials; immunoassays suffer from limited epitopes and false positive results, while MS involves a complicated and time-consuming workflow.
Nanopore technology, distinguished by its capability of real-time single-molecule sensing, has shown great prospects in polypeptide analysis, potentially offering distinct advantages over the forementioned methods in clinical trials. Recent progress has been made to sense PTMs deep within full-length polypeptides. By leveraging the recent advances in nanopore technology and the development of numerous site-specific anti-Tau binders, this project aims to exploit a single-molecule toolkit for detecting Tau of varying lengths and clinically relevant phosphorylations across full-length Tau proteoforms. To achieve that, we will leverage engineered nanopores developed by the host lab to facilitate translocation of intact Tau proteoforms, alongside a binder-assisted strategy to amplify the signals of targeted truncations and phosphorylations while minimizing interference from non-target backgrounds. Should our goal accomplished, it could provide a sensitive and robust diagnostic tool for the assessment and monitoring of tauopathies, as well as contribute to the advancement of tauopathies research to single-molecular resolution.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2024-PF-01

See all projects funded under this call

Coordinator

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Net EU contribution
€ 260 347,92
Address
WELLINGTON SQUARE UNIVERSITY OFFICES
OX1 2JD Oxford
United Kingdom
Region
South East (England) Berkshire, Buckinghamshire and Oxfordshire Oxfordshire
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data